Document Detail

Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality?
MedLine Citation:
PMID:  23199318     Owner:  NLM     Status:  MEDLINE    
T cells reactive to lipids and restricted by major histocompatibility complex (MHC) class I-like molecules represent more than 15% of all lymphocytes in human blood. This heterogeneous population of innate cells includes the invariant natural killer T cells (iNK T), type II NK T cells, CD1a,b,c-restricted T cells and mucosal-associated invariant T (MAIT) cells. These populations are implicated in cancer, infection and autoimmunity. In this review, we focus on the role of these cells in autoimmunity. We summarize data obtained in humans and preclinical models of autoimmune diseases such as primary biliary cirrhosis, type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis and atherosclerosis. We also discuss the promise of NK T cell manipulations: restoration of function, specific activation, depletion and the relevance of these treatments to human autoimmune diseases.
Y Simoni; J Diana; L Ghazarian; L Beaudoin; A Lehuen
Related Documents :
17997718 - Human multipotent adipose-derived stem cells restore dystrophin expression of duchenne ...
24850218 - Genetic and epigenetic control of early lymphocyte development.
24453518 - Ovarian stem cells-the pros and cons.
23299888 - Germinal centre protein hgal promotes lymphoid hyperplasia and amyloidosis via bcr-medi...
8379688 - Studies on the effects of a high dose uva-1 radiation therapy on surface markers and fu...
19038008 - Histological and immunophenotypic changes in 59 cases of b-cell non-hodgkin's lymphoma ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Clinical and experimental immunology     Volume:  171     ISSN:  1365-2249     ISO Abbreviation:  Clin. Exp. Immunol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-03     Completed Date:  2013-02-19     Revised Date:  2014-01-10    
Medline Journal Info:
Nlm Unique ID:  0057202     Medline TA:  Clin Exp Immunol     Country:  England    
Other Details:
Languages:  eng     Pagination:  8-19     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors. Clinical and Experimental Immunology © 2012 British Society for Immunology.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arthritis, Rheumatoid / immunology
Atherosclerosis / immunology
Autoimmunity / immunology*
Clinical Trials, Phase I as Topic
Diabetes Mellitus, Type 1 / immunology
Galactosylceramides / therapeutic use
Liver Cirrhosis, Biliary / immunology
Lupus Erythematosus, Systemic / immunology
Multiple Sclerosis / immunology
Natural Killer T-Cells / drug effects,  immunology*
Psoriasis / immunology
Reg. No./Substance:
0/Galactosylceramides; 0/alpha-galactosylceramide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  CD73 and adenosine generation in the creation of regulatory microenvironments.
Next Document:  Heat shock protein bystander antigens for peptide immunotherapy in autoimmune disease.